therapeuticЮжно-Российский журнал терапевтической практикиSouth Russian Journal of Therapeutic Practice2712-8156РостГМУ10.21886/2712-8156-2023-4-3-22-26therapeutic-374Research ArticleОБЗОРЫREVIEWSВлияние терапии язвенного колита на бактериальный профиль микробиоты толстой кишкиImpact of ulcerative colitis therapy on the bacterial profile of the intestinal microbiotahttps://orcid.org/0000-0003-4054-9180ТарасоваГ. Н.TarasovaG. N.

Тарасова Галина Николаевна - профессор, доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней

Tarasova Galina N. - Dr.Sci. (Med.), Prof., Chair of Internal Disease Propedeutics

doctor-gastro@yandex.ruhttps://orcid.org/0000-0002-9268-3827ЗубоваА. Д.ZubovaA. D.

Зубова Анна Дмитриевна - врач-терапевт Медико-санитарной части МВД России по Ростовской области

Zubova Anna D. - Physician, Medical and Sanitary Unit of the Ministry of Internal Affairs of Russia for the Rostov Region.

Rostov-on-Don

anna-d-zubova@yandex.ruФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава РоссииРоссияRostov State Medical UniversityRussian FederationМедико-санитарная часть МВД России по Ростовской областиРоссияMedical and Sanitary Unit of the Ministry of Internal Affairs of Russia for the Rostov RegionRussian Federation202325092023432226Copyright © Тарасова Г.Н., Зубова А.Д., 20232023Тарасова Г.Н., Зубова А.Д.Tarasova G.N., Zubova A.D.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.therapeutic-j.ru/jour/article/view/374

Воспалительные заболевания кишечника представляют гетерогенную группу хронических заболеваний, возникающих в результате нарушения процессов взаимодействия иммунной системы слизистой оболочки и комменсальной экосистемы толстой кишки. Ключевая роль микробиоты кишечника в патогенезе язвенного колита, а также определение её как фактора, детерминистически влияющего на статус иммунной активации и тяжесть заболевания, подтверждается многими исследованиями. Накапливающиеся данные свидетельствуют о том, что неантибактериальные препараты способны модулировать состав кишечной микробиоты, что в свою очередь может определять эффективность фармакологической терапии и клинический исход. В статье представлен обзор литературы по теме влияния на бактериальное сообщество толстой кишки препаратов, используемых в терапии язвенного колита.

Inflammatory bowel diseases represent a heterogeneous group of chronic diseases occurring as a result of disruption of interaction processes between the mucosal immune system and the colon commensal ecosystem. The key role of the intestinal microbiota in the pathogenesis of ulcerative colitis, as well as its definition as a deterministic factor influencing the status of immune activation and the severity of the disease, is confirmed in many studies. Accumulating evidence suggests that non-antibacterial drugs are able to modulate the composition of the intestinal microbiota, which in turn may determine the effectiveness of pharmacological therapy and the clinical outcome. The article presents a review of literature on the impact of drugs used in the treatment of ulcerative colitis on the bacterial community of the colon.

обзормикробиотаязвенный колитreviewmicrobiotaulcerative colitisИсследование не имело спонсорской поддержкиReferencesGraham D.B., Xavier R.J. Pathway Paradigms Revealed from the Genetics of Inflammatory Bowel Disease. Nature. 2020;578(7796):527-539. doi: 10.1038/s41586-020-2025-2.Graham D.B., Xavier R.J. Pathway Paradigms Revealed from the Genetics of Inflammatory Bowel Disease. Nature. 2020;578(7796):527-539. doi: 10.1038/s41586-020-2025-2.Lane E.R., Zisman T.L., Suskind D.L. The microbiota in inflammatory bowel disease: current and therapeutic insights. Journal of Inflammation Research. 2017;10:63-73. doi: 10.2147/JIR.S116088.Lane E.R., Zisman T.L., Suskind D.L. The microbiota in inflammatory bowel disease: current and therapeutic insights. Journal of Inflammation Research. 2017;10:63-73. doi: 10.2147/JIR.S116088.Crouwel F., Buiter H.J., Boer N.K. Gut microbiota-driven drug metabolism in inflammatory bowel disease. Journal of Crohn's and Colitis. 2020;15(2):307-315. doi: 10.1093/ecco-jcc/jjaa143.Crouwel F., Buiter H.J., Boer N.K. Gut microbiota-driven drug metabolism in inflammatory bowel disease. Journal of Crohn's and Colitis. 2020;15(2):307-315. doi: 10.1093/ecco-jcc/jjaa143.Mentella М.C., Scaldaferri F., Pizzoferrato M., Gasbarrini A., Miggiano G.A. Nutrition, IBD and Gut Microbiota: A Review. Nutrients. 2020;12(4):944. doi: 10.3390/nu12040944.Mentella М.C., Scaldaferri F., Pizzoferrato M., Gasbarrini A., Miggiano G.A. Nutrition, IBD and Gut Microbiota: A Review. Nutrients. 2020;12(4):944. doi: 10.3390/nu12040944.Sultan S., El-Mowafy M., Elgaml A., Ahmed T., Hassan H., Mottawea W. Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease. Frontiers in Physiology. 2021;12:715506. doi: 10.3389/fphys.2021.715506.Sultan S., El-Mowafy M., Elgaml A., Ahmed T., Hassan H., Mottawea W. Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease. Frontiers in Physiology. 2021;12:715506. doi: 10.3389/fphys.2021.715506.Ni J., Wu G.D., Albenberg L., Tomov V.T. Gut microbiota and IBD: causation or correlation? Nature Reviews Gastroenterology & Hepatology. 2017;14(10):573-584. doi: 10.1038/nrgastro.2017.88.Ni J., Wu G.D., Albenberg L., Tomov V.T. Gut microbiota and IBD: causation or correlation? Nature Reviews Gastroenterology & Hepatology. 2017;14(10):573-584. doi: 10.1038/nrgastro.2017.88.Lee M., Chang E.B. Inflammatory Bowel Diseases (IBD) and the Microbiome-Searching the Crime Scene for Clues. Gastroenterology. 2021;160(2):524-537. doi: 10.1053/j.gastro.2020.09.056.Lee M., Chang E.B. Inflammatory Bowel Diseases (IBD) and the Microbiome-Searching the Crime Scene for Clues. Gastroenterology. 2021;160(2):524-537. doi: 10.1053/j.gastro.2020.09.056.Oka A., Sartor B. Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases. Digestive Diseases and Sciences. 2020;65(3): 757–788. doi: 10.1007/s10620-020-06090-z.Oka A., Sartor B. Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases. Digestive Diseases and Sciences. 2020;65(3): 757–788. doi: 10.1007/s10620-020-06090-z.He X.X., Li H.H., Yan P.G., Meng X.C., Chen C.Y., Li K.M. et al. Relationship between clinical features and intestinal microbiota in Chinese patients with ulcerative colitis. World Journal of Gastroenterology. 2021;27(28):4722-4737. doi: 10.3748/wjg.v27.i28.4722.He X.X., Li H.H., Yan P.G., Meng X.C., Chen C.Y., Li K.M. et al. Relationship between clinical features and intestinal microbiota in Chinese patients with ulcerative colitis. World Journal of Gastroenterology. 2021;27(28):4722-4737. doi: 10.3748/wjg.v27.i28.4722.López R.L., Burgos M.J., Gálvez A., Pulido R.P. The human gastrointestinal tract and oral microbiota in inflammatory bowel disease: a state of the science review. APMIS. 2017;125(1):3-10. doi: 10.1111/apm.12609.López R.L., Burgos M.J., Gálvez A., Pulido R.P. The human gastrointestinal tract and oral microbiota in inflammatory bowel disease: a state of the science review. APMIS. 2017;125(1):3-10. doi: 10.1111/apm.12609.Xu J., Chen N., Wu Z., Song Y., Zhang Y., Wu N., et al. 5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis. Frontiers in Microbiology. 2018;9:1274. doi: 10.3389/fmicb.2018.01274.Xu J., Chen N., Wu Z., Song Y., Zhang Y., Wu N., et al. 5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis. Frontiers in Microbiology. 2018;9:1274. doi: 10.3389/fmicb.2018.01274.Britton G.J., Contijoch E.J., Mogno I., Vennaro O.H., Llewellyn S.R., Ng R., et al. Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in Mice. Immunity. 2019;50(1):212-224.e4. doi: 10.1016/j.immuni.2018.12.015.Britton G.J., Contijoch E.J., Mogno I., Vennaro O.H., Llewellyn S.R., Ng R., et al. Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in Mice. Immunity. 2019;50(1):212-224.e4. doi: 10.1016/j.immuni.2018.12.015.Vila A.V., Collij V., Sanna S., Sinha T., Imhann F., Bourgonje A.R., et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nature. 2020;11(1):362. doi: 10.1038/s41467-019-14177-z.Vila A.V., Collij V., Sanna S., Sinha T., Imhann F., Bourgonje A.R., et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nature. 2020;11(1):362. doi: 10.1038/s41467-019-14177-z.Seyedian S.S., Nokhostin F., Malamir M.D. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. Journal of Medicine and Life. 2019;12(2):113-122. doi: 10.25122/jml-2018-0075.Seyedian S.S., Nokhostin F., Malamir M.D. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. Journal of Medicine and Life. 2019;12(2):113-122. doi: 10.25122/jml-2018-0075.Cevallos S.A., Lee J.Y., Velazquez E.M., Foegeding N.J., Shelton C.D., Tiffany C.R., et al. 5-Aminosalicylic Acid Ameliorates Colitis and Checks Dysbiotic Escherichia coli Expansion by Activating PPAR-γ Signaling in the Intestinal Epithelium. mBio. 2021;12(1):e03227-20. doi: 10.1128/mBio.03227-20.Cevallos S.A., Lee J.Y., Velazquez E.M., Foegeding N.J., Shelton C.D., Tiffany C.R., et al. 5-Aminosalicylic Acid Ameliorates Colitis and Checks Dysbiotic Escherichia coli Expansion by Activating PPAR-γ Signaling in the Intestinal Epithelium. mBio. 2021;12(1):e03227-20. doi: 10.1128/mBio.03227-20.Dai L., Tang Y., Zhou W., Dang Y., Sun Q., Tang Z., et al. Gut Microbiota and Related Metabolites Were Disturbed in Ulcerative Colitis and Partly Restored After Mesalamine Treatment. Frontiers in Pharmacology. 2021;11:620724. doi: 10.3389/fphar.2020.620724.Dai L., Tang Y., Zhou W., Dang Y., Sun Q., Tang Z., et al. Gut Microbiota and Related Metabolites Were Disturbed in Ulcerative Colitis and Partly Restored After Mesalamine Treatment. Frontiers in Pharmacology. 2021;11:620724. doi: 10.3389/fphar.2020.620724.Kucharzik T., Koletzko S., Kannengiesser K., Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms. Deutsches Ärzteblatt International. 2020;117(33-34):564-574. doi: 10.3238/arztebl.2020.0564.Kucharzik T., Koletzko S., Kannengiesser K., Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms. Deutsches Ärzteblatt International. 2020;117(33-34):564-574. doi: 10.3238/arztebl.2020.0564.Atherly T., Rossi G., White R., Seo Y.J., Wang C., Ackermann M., et al. Glucocorticoid and dietary effects on mucosal microbiota in canine inflammatory bowel disease. PLOS One. 2019;14(12):e0226780. doi: 10.1371/journal.pone.0226780.Atherly T., Rossi G., White R., Seo Y.J., Wang C., Ackermann M., et al. Glucocorticoid and dietary effects on mucosal microbiota in canine inflammatory bowel disease. PLOS One. 2019;14(12):e0226780. doi: 10.1371/journal.pone.0226780.Zhang J., Feng D., Law H.K., Wu Y., Zhu G.H., Huang W.Y., et al. Integrative Analysis of Gut Microbiota and Fecal Metabolites in Rats after Prednisone Treatment. Microbiology Spectrum. 2021;9(3):e0065021. doi: 10.1128/Spectrum.00650-21.Zhang J., Feng D., Law H.K., Wu Y., Zhu G.H., Huang W.Y., et al. Integrative Analysis of Gut Microbiota and Fecal Metabolites in Rats after Prednisone Treatment. Microbiology Spectrum. 2021;9(3):e0065021. doi: 10.1128/Spectrum.00650-21.Schirmer M., Denson L., Vlamakis H., Franzosa E.A., Thomas S., Gotman N.M., et al. Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. Cell Host & Microbe. 2018;24(4):600-610.e4. doi: 10.1016/j.chom.2018.09.009.Schirmer M., Denson L., Vlamakis H., Franzosa E.A., Thomas S., Gotman N.M., et al. Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. Cell Host & Microbe. 2018;24(4):600-610.e4. doi: 10.1016/j.chom.2018.09.009.Cai Z., Wang S., Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Frontiers in Medicine. 2021;8:765474. doi: 10.3389/fmed.2021.765474.Cai Z., Wang S., Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Frontiers in Medicine. 2021;8:765474. doi: 10.3389/fmed.2021.765474.Liu F., Ma R., Riordan S.M., Grimm M.C., Liu L., Wang Y., et al. Azathioprine, Mercaptopurine, and 5-Aminosalicylic Acid Affect the Growth of IBD-Associated Campylobacter Species and Other Enteric Microbes. Frontiers in Microbiology. 2017;8:527. doi: 10.3389/fmicb.2017.00527.Liu F., Ma R., Riordan S.M., Grimm M.C., Liu L., Wang Y., et al. Azathioprine, Mercaptopurine, and 5-Aminosalicylic Acid Affect the Growth of IBD-Associated Campylobacter Species and Other Enteric Microbes. Frontiers in Microbiology. 2017;8:527. doi: 10.3389/fmicb.2017.00527.Zhou B., Xia X., Wang P., Chen S., Yu C., Huang R., et al. Induction and Amelioration of Methotrexate-Induced Gastrointestinal Toxicity are Related to Immune Response and Gut Microbiota. EBioMedicine. 2018;33:122-133. doi: 10.1016/j.ebiom.2018.06.029.Zhou B., Xia X., Wang P., Chen S., Yu C., Huang R., et al. Induction and Amelioration of Methotrexate-Induced Gastrointestinal Toxicity are Related to Immune Response and Gut Microbiota. EBioMedicine. 2018;33:122-133. doi: 10.1016/j.ebiom.2018.06.029.Letertre M.P., Munjoma N., Wolfer K., Pechlivanis A., McDonald J.A., Hardwick R.N., et al. A Two-Way Interaction between Methotrexate and the Gut Microbiota of Male Sprague-Dawley Rats. Journal of Proteome Research. 2020;19(8):3326-3339. doi: 10.1021/acs.jproteome.0c00230.Letertre M.P., Munjoma N., Wolfer K., Pechlivanis A., McDonald J.A., Hardwick R.N., et al. A Two-Way Interaction between Methotrexate and the Gut Microbiota of Male Sprague-Dawley Rats. Journal of Proteome Research. 2020;19(8):3326-3339. doi: 10.1021/acs.jproteome.0c00230.Hoffmann P., Wehling C., Krisam J., Pfeiffenberger J., Belling N., Gauss A. et al. Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis. World Journal of Gastroenterology. 2019;25(13):1603–1617. doi: 10.3748/wjg.v25.i13.1603.Hoffmann P., Wehling C., Krisam J., Pfeiffenberger J., Belling N., Gauss A. et al. Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis. World Journal of Gastroenterology. 2019;25(13):1603–1617. doi: 10.3748/wjg.v25.i13.1603.O'Reilly С., O’Sullivan O., Cotter P.D., O’Connor P.M., Shanahan F., Cullen A., et al. Encapsulated cyclosporine does not change the composition of the human microbiota when assessed ex vivo and in vivo. Journal of Medical Microbiology. 2020;69(6): 854–863. doi: 10.1099/jmm.0.001130O'Reilly С., O’Sullivan O., Cotter P.D., O’Connor P.M., Shanahan F., Cullen A., et al. Encapsulated cyclosporine does not change the composition of the human microbiota when assessed ex vivo and in vivo. Journal of Medical Microbiology. 2020;69(6): 854–863. doi: 10.1099/jmm.0.001130Zhang Z., Liu L. Tang H., Jiao W., Zeng S., Xu Y. et al. Immunosuppressive effect of the gut microbiome altered by high-dose tacrolimus in mice. American Journal of Transplantation. 2018; 8(7):1646-1656. doi: 10.1111/ajt.14661.Zhang Z., Liu L. Tang H., Jiao W., Zeng S., Xu Y. et al. Immunosuppressive effect of the gut microbiome altered by high-dose tacrolimus in mice. American Journal of Transplantation. 2018; 8(7):1646-1656. doi: 10.1111/ajt.14661.Pantavou K., Yiallourou A.I., Piovani D., Evripidou D., Danese S., Peyrin-Biroulet L.,et al. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. United European Gastroenterology Journal. 2019;7(10):1285-1303. doi: 10.1177/2050640619883566.Pantavou K., Yiallourou A.I., Piovani D., Evripidou D., Danese S., Peyrin-Biroulet L.,et al. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. United European Gastroenterology Journal. 2019;7(10):1285-1303. doi: 10.1177/2050640619883566.Estevinho M.M., Rocha C., Correia L., Lago P., Ministro P., Portela F., et al. Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: A Systematic Review. Clinical Gastroenterology and Hepatology. 2020;18(5):1054-1069. doi: 10.1016/j.cgh.2019.08.063.Estevinho M.M., Rocha C., Correia L., Lago P., Ministro P., Portela F., et al. Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: A Systematic Review. Clinical Gastroenterology and Hepatology. 2020;18(5):1054-1069. doi: 10.1016/j.cgh.2019.08.063.Seong G., Kim N., Joung J.G., Kim E.R., Chang D.K., Chun J., et al. Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle. Microorganisms. 2020;8(6):874. doi: 10.3390/microorganisms8060874.Seong G., Kim N., Joung J.G., Kim E.R., Chang D.K., Chun J., et al. Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle. Microorganisms. 2020;8(6):874. doi: 10.3390/microorganisms8060874.Zhou Y., Xu Z. Z., He Y., Yang Y., Liu L., Lin Q., et al. Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction. mSystems. 2018;3(1):e00188-17. doi: 10.1128/mSystems.00188-17.Zhou Y., Xu Z. Z., He Y., Yang Y., Liu L., Lin Q., et al. Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction. mSystems. 2018;3(1):e00188-17. doi: 10.1128/mSystems.00188-17.Alatawi Н., Mosli M., Saadah O.I., Annese V., Al-Hindi R., Alatawy M., et al. Attributes of intestinal microbiota composition and their correlation with clinical primary non-response to anti-TNF-α agents in inflammatory bowel disease patients. Bosnian Journal of Basic Medical Sciences. 2022;22(3):412-426. doi: 10.17305/bjbms.2021.6436.Alatawi Н., Mosli M., Saadah O.I., Annese V., Al-Hindi R., Alatawy M., et al. Attributes of intestinal microbiota composition and their correlation with clinical primary non-response to anti-TNF-α agents in inflammatory bowel disease patients. Bosnian Journal of Basic Medical Sciences. 2022;22(3):412-426. doi: 10.17305/bjbms.2021.6436.Ananthakrishnan A.N., Luo C., Yajnik V., Khalili H., Garber J.J., Stevens B.W., et al. Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. Cell Host & Microbe. 2017;21(5):603-610.e3. doi: 10.1016/j.chom.2017.04.010.Ananthakrishnan A.N., Luo C., Yajnik V., Khalili H., Garber J.J., Stevens B.W., et al. Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. Cell Host & Microbe. 2017;21(5):603-610.e3. doi: 10.1016/j.chom.2017.04.010.Effenberger M., Reider S., Waschina S., Bronowski C., Enrich B., Adolph T.E., et al. Microbial Butyrate Synthesis Indicates Therapeutic Efficacy of Azathioprine in IBD Patients. Journal of Crohn's and Colitis. 2021;15(1):88-98. doi: 10.1093/ecco-jcc/jjaa152.Effenberger M., Reider S., Waschina S., Bronowski C., Enrich B., Adolph T.E., et al. Microbial Butyrate Synthesis Indicates Therapeutic Efficacy of Azathioprine in IBD Patients. Journal of Crohn's and Colitis. 2021;15(1):88-98. doi: 10.1093/ecco-jcc/jjaa152.

The authors declare that there are no conflicts of interest present.